Video
Dr. Eggener on active surveillance: “There’s superb long-term outcomes”
Author(s):
"It’s an important topic to debate,” says Scott E. Eggener, MD.
Video Player is loading.
In this video, Scott Eggener, MD, discusses the key points of the debate, “What is the Preferred Approach for Low Risk Prostate Cancer?” being presented today at the 2021 Society of Urologic Oncology Annual Meeting. Eggener is a Bruce and Beth White Family professor of surgery and radiology, vice chair of the section of urology, and director of the High Risk and Advanced Prostate Cancer Clinic at the University of Chicago Medical Center in Chicago, Illinois.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
